Skip to main content

INVESTORS & MEDIA

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent News
05/02/19
- Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs – - SER-287 Fast Track designation obtained for active mild-to-moderate ulcerative colitis; Phase 2b study enrollment expected to be completed by mid-2020 and top-line
04/29/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2019-- Seres Therapeutics, Inc . (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on May 2, 2019 at 8:30 a.m. ET to discuss first quarter 2019 results and provide a general business update.
04/02/19
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (poster title “Leveraging gut microbiota networks to impact tumor immunotherapy”) 1 will be
There are currently no events to display.
Stock Quote
:
 
 

E-mail Alerts

Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Request Information

Obtain investor relations information by contacting us.

More

Back to top